Completed PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT00809848

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Sponsor: Allergan

Interventions AGN-210669 ophthalmic solution, 0.025% AGN-210669 ophthalmic solution, 0.05% AGN-210669 ophthalmic solution, 0.075% AGN-210669 vehicle ophthalmic solution bimatoprost ophthalmic solution 0.03%

Updated 8 times since 2017 Last updated: Aug 13, 2013 Started: Feb 28, 2009 Primary completion: May 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Glaucoma and Ocular Hypertension, this trial is completed. The trial is conducted by Allergan and has accumulated 8 data snapshots since 2009. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Artesia, United States